N/A N=265 Colorectal Cancer: Screening vs. Non-Screening
Colorectal Cancer · Screening
Primary: Colorectal Cancer Stage (pTNM) — 46; 85 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=204 Adjuvant HIPEC in High Risk Colon Cancer
Colorectal Neoplasms · Peritoneal Neoplasms
Primary: Peritoneal Recurrence Free Survival at 18 Months — 79; 80 participants
N/A N=8 Translation of Colorectal Cancer Screening Guidelines to Practice: A System Intervention
Colorectal Cancer
Primary: Percent of Patients Receiving GI Consult for FOBT+ Results — 39; 47; 64; 51 percent patients receiving GI consult
N/A N=120 Healthy Eating for Colon Cancer Prevention
Colon Cancer
Primary: Adherence to Dietary Goals — 89; 85 percentage of participants meeting goals
N/A N=41,193 Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Colorectal Cancer
Primary: FIT Completion — 10.4; 13.9 Model based percentage of participants — p=.05
Phase 2 N=20 Cellular Immune Augmentation in Colon and Rectal Cancer
Colon Cancer · Rectal Cancer
Primary: Participants Exhibiting Immune Response — 11 Participants
N/A N=5,970 Increasing Colorectal Cancer Screening in a Safety-net Health System With a Focus on the Uninsured: Benefits and Costs
Colorectal Cancer
Primary: Colorectal Cancer Screening Participation, Defined as Completion of a Guaiac or Immunochemical Stool Occult Blood Test, Colonoscopy, Sigmoidoscopy, or Barium Enem…
N/A N=269 Complete Histologic Resection of Adenomatous Polyps?
Adenomatous Polyps
Primary: Percent of Incompletely Resected Adenomatous Polyps — 10.1 percentage of incomplete resection
Phase 2 N=16 Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
Colon Cancer · Rectal Cancer
Primary: Efficacy of Lymphoseek for Detection of Sentinel Nodes — 16 Participants
N/A N=35 Fiber and Fish Oil Supplements for the Prevention of Colorectal Cancer
Healthy Subject
Primary: Feasibility and Retention for a Trial With Daily Doses of 35 g of Fiber and 6.2 g of EPA +DHA (and Corresponding Comparators) — 14; 15; 1; 1 Participants
N/A N=2,600 The National CT Colonography Trial
Colorectal Cancer
Primary: Number of Participants With Advanced Adenomas (>=10mm) as Determined by Colonoscopy (Per Patient) — 109; 2422 Participants
N/A N=99 Laparoscopic Complete Mesocolic Excision on Colon Cancer
Operation Finding · Complications · Pathology
Primary: Histopathological Outcomes Obtained Through the Surgeries — 20.3; 19.2 nodes
Phase 2 N=306 A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Colorectal Cancer
Primary: Percentage of Participants With Disease Progression or Death — 86.14; 90.20; 88.35 percentage of participants
N/A N=477 Evaluating Strategies to Present Colon Cancer Screening Information
Colonic Neoplasms · Colorectal Neoplasms · Colonic Diseases
Primary: Intentions to Get Screened for Colon Cancer — 68.64; 65.51; 64.30 units on a 0-100 scale — p=.362
Phase 2 N=75 Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
Colon Cancer · Colorectal Cancer
Primary: Maximum Tolerated Dose (MTD) of Celebrex in Combination With EPO906 — 9 mg/m2
Phase 4 N=360 Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage
Spinal Cord Injury
Primary: Quality of Bowel Preparation — 3.4; 2.5; 3.6; 7.4 units on a scale
Phase 2 N=79 Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer
Colon Cancer · Precancerous Condition · Rectal Cancer
Primary: Change of a Spectral Biomarker for Colonic Carcinogenesis (Called Spectral Slope or SPEC) From Baseline to 3 Months. — 40.72; 37.54; 43.45; 37.52 micron^-1 — p=0.11
N/A N=889 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer
Anxiety Disorder · Cognitive/Functional Effects · Colorectal Cancer
Primary: Disease-free Survival — 80.3; 73.9 percentage of participants — p=0.02
Phase 2 N=90 Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
Colorectal Cancer
Primary: Major Morbidity Related to the Intact Primary Tumor — 16.3 probability of major morbidity (%)
Phase 3 N=2,526 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Colorectal Cancer
Primary: Disease-free Survival — 73.4; 76.3 percentage of participants — p=0.12
Phase 2 N=64 Neoadjuvant Therapy for Locally Advanced Colon Cancer
Colon Cancer · Neoadjuvant Therapy
Primary: Tumor Regression Rate of MSS/pMMR Patients — 7 Participants
N/A N=1,855 The Colorectal Breath Analysis (COBRA) Study
Colorectal Cancer · Colorectal Polyps · Colorectal Adenocarcinoma
Primary: Determine the Diagnostic Accuracy of the Proposed Breath Test for Detection of Colorectal Cancer in All Patients — 79; 86 percentage of true cases
Phase 2 N=13 Genistein in Treatment of Metastatic Colorectal Cancer
Colon Cancer · Rectal Cancer · Colorectal Cancer
Primary: Number of Adverse Events — 250; 119; 24; 0 events
Phase 2 N=17 Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
Colorectal Cancer
Primary: Progression-free Survival (PFS) — 55 Days
Phase 3 N=3,397 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
Adenocarcinoma of the Colon · Stage III Colon Cancer
Primary: Disease-free Survival (Arms A and D: Wild-type KRAS Patients) — 74.6; 71.5 percentage of participants
Phase 2 N=40 Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib
Colorectal Adenoma · Colorectal Carcinoma
Primary: Number of Subjects Witha Change (IMPROVEMENT) in Colo-rectal Adenocarcinoma as Measured by Cyclooxygenase-2 Activity After 7 Days of Celecoxib — 2.0; 2.0 Participant
N/A N=1,111 Helping Patients and Providers Make Better Decisions About Colorectal Cancer Screening
Cancer Screening Tests
Primary: Number of Participants Who Completed Colorectal Cancer Screening — 110; 95; 113; 113 Participants
N/A N=12 Studies in Patients With Low Anterior Resection Syndrome (LARS)
Anterior Resection Syndrome · Bowel Dysfunction
Primary: Change of Anorectal Pressure Assessed With the Fecobionics Device — 9.8 cmH2O
N/A N=11,016 Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Colorectal Neoplasms · Digestive System Diseases · Colonic Diseases
Primary: Sensitivity and Specificity of the Exact CRC Screening Test With Comparison to Colonoscopy, Both With Respect to Cancer. — 92.3; 73.8; 93.3; 73.3 percent
Phase 2 N=87 Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer
Adenomatous Polyp · Colorectal Carcinoma
Primary: Difference (After Treatment Minus Before Treatment) of EGFR Expression — 0.17; -0.40; 0.21 ng/ml